| n | ALDH1A1 expression | P value | |||
---|---|---|---|---|---|---|
– | + | ++ | +++ | |||
Age (years) | 147 | 52.2 ± 11.9 | 51.6 ± 13.0 | 53.2 ± 13.0 | 48.5 ± 12.7 | 0.682 |
Tumor size (cm) | 147 | 3.9 ± 0.6 | 2.6 ± 0.2 | 2.9 ± 0.6 | 3.9 ± 0.5 | 0.103 |
Lymph node involvement | 115 | 45 (39.1%) | 45 (39.1%) | 9 (4.0%) | 16 (13.9%) | 0.389 |
TNM stages | Â | Â | Â | Â | Â | Â |
I | 14 | 4 (28.6%) | 8 (57.1%) | 1 (7.1%) | 1 (7.1%) | 0.177 |
II | 56 | 19 (33.9%) | 25 (44.6%) | 6 (10.7%) | 6 (10.7%) | Â |
III | 76 | 31 (40.8%) | 29 (38.2%) | 5 (6.6%) | 11 (14.5%) | Â |
IV | 1 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | Â |
NOTCH1 expression | Â | Â | Â | Â | Â | |
– | 9 | 7 (77.8%) | 2 (22.2%) | 0 (0.0%) | 0 (0.0%) | 0.044 |
+ | 26 | 7 (26.9%) | 17 (65.4%) | 2 (7.7%) | 0 (0.0%) | Â |
++ | 24 | 10 (41.7%) | 8 (33.3%) | 1 (4.2%) | 5 (20.8%) | Â |
+++ | 88 | 30 (34.1%) | 36 (40.9%) | 8 (9.1%) | 14 (15.9%) | Â |
Ki67 expression | Â | Â | Â | Â | Â | Â |
– | 79 | 38 (48.1%) | 35 (44.3%) | 6 (7.6%) | 0 (0.0%) | 0.001 |
+ | 68 | 16 (23.5%) | 28 (41.2%) | 5 (7.4%) | 19 (27.9%) | Â |
P53 expression | Â | Â | Â | Â | Â | Â |
– | 100 | 35 (35.0%) | 45 (45.0%) | 8 (8.0%) | 12 (12.0%) | 0.823 |
+ | 47 | 19 (40.4%) | 18 (38.3%) | 3 (6.4%) | 7 (14.9%) | Â |
ER expression | Â | Â | Â | Â | Â | Â |
– | 90 | 34 (37.8%) | 35 (38.9%) | 6 (6.7%) | 15 (16.7%) | 0.303 |
+ | 57 | 20 (35.1%) | 28 (47.4%) | 5 (8.8%) | 4 (7.0%) | Â |
PR expression | Â | Â | Â | Â | Â | Â |
– | 83 | 27 (32.5%) | 38 (45.8%) | 5 (6.0%) | 13 (15.7%) | 0.400 |
+ | 64 | 27 (42.2%) | 25 (39.1%) | 6 (9.4%) | 6 (9.4%) | Â |
HER2 expression | Â | Â | Â | Â | Â | |
– | 77 | 32 (41.6%) | 32 (41.6%) | 4 (5.2%) | 9 (11.7%) | 0.492 |
+ | 70 | 22 (31.4%) | 31 (44.3%) | 7 (10.0%) | 10 (14.3%) | Â |
Triple negativity features* | Â | Â | Â | Â | ||
– | 108 | 40 (37.0%) | 44 (40.7%) | 10 (9.3%) | 14 (13.0%) | 0.541 |
+ | 39 | 14 (35.9%) | 19 (48.7%) | 1 (2.6%) | 5 (12.8%) | Â |
Local recurrence | Â | Â | Â | Â | ||
Present | 40 | 8 (20.0%) | 20 (50.0%) | 6 (15.0%) | 6 (15.0%) | 0.027 |
Absent | 107 | 46 (43.0%) | 43(40.2%) | 5 (4.7%) | 13 (12.1%) | Â |
Distant metastasis | Â | Â | Â | Â | ||
Present | 51 | 21 (41.1%) | 20 (39.2%) | 3 (5.9%) | 7 (13.7%) | 0.809 |
Absent | 96 | 33 (34.3%) | 43 (44.8%) | 8 (8.3%) | 12 (12.5%) | Â |